Last updated on February 2019

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL


Brief description of study

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Detailed Study Description

This is an open-label, single arm, dose escalation study in patients with relapsed or refractory CLL. Treatment will be administered on an outpatient basis and all patients will receive CYC065 over 4-hour infusion once every 2 weeks on Day 1 and Day 15 in combination with venetoclax. One treatment cycle is 4 weeks.

Clinical Study Identifier: NCT03739554

Find a site near you

Start Over

MD Anderson Cancer Center

Houston, TX United States
  Connect »